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Abstract
Background: Mycobacterium ulcerans (MU) is responsible for disfiguring skin lesions and is endemic on the Bellarine
peninsula of southeastern Australia. Antibiotics have been shown to be highly effective in sterilizing lesions and preventing
disease recurrences when used alone or in combination with surgery. Our practice has evolved to using primarily oral
medical therapy.
Methods: From a prospective cohort of MU patients managed at Barwon Health, we describe those treated with primary
medical therapy defined as treatment of a M. ulcerans lesion with antimicrobials either alone or in conjunction with limited
surgical debridement.
Results: From 1/10/2010 through 31/12/11, 43 patients were treated with exclusive medical therapy, of which 5 (12%) also
underwent limited surgical debridement. The median patient age was 50.2 years, and 86% had WHO category 1 and 91%
ulcerative lesions. Rifampicin was combined with ciprofloxacin in 30 (70%) and clarithromycin in 12 (28%) patients. The
median duration of antibiotic therapy was 56 days, with 7 (16%) receiving less than 56 days. Medication side effects
requiring cessation of one or more antibiotics occurred in 7 (16%) patients. Forty-two (98%) patients healed without
recurrence within 12 months, and 1 patient (2%) experienced a relapse 4 months after completion of 8 weeks of
antimicrobial therapy.
Conclusion: Our experience demonstrates the efficacy and safety of primary oral medical management of MU infection with
oral rifampicin-based regimens. Further research is required to determine the optimal and minimum durations of antibiotic
therapy, and the most effective antibiotic dosages and formulations for young children.
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Introduction
Buruli ulcer, also known as Bairnsdale ulcer, Daintree ulcer, or
Mossman ulcer is a necrotising infection of skin and subcutaneous
tissue caused by Mycobacterium ulcerans (MU) [1]. The major burden
of disease is found in tropical climates, but cases have been
reported from 33 countries worldwide [2]. M.ulcerans infection has
become endemic on Victoria’s Bellarine Peninsula in South-
eastern Australia [1]
Surgical management was traditionally the standard treatment
for M. ulcerans disease [1,3], however recurrence of infection
ensued in 17–32% of patients [4,5]. Evidence of the effectiveness
of antimicrobials used alone or combined with surgery [4–7], has
led to an evolution of our standard treatment practice over the last
15 years to now comprise combination antimicrobial therapy with
limited surgical debridement when required [5,8]. Improved
awareness in our region about MU lesions in the community has
resulted in earlier referral of patients with smaller lesions to our
department at Barwon Health [9].
We previously advocated for further studies using oral antibiotic
regimens [7]. Here we describe results from an observational
cohort of patients from South-eastern Australia managed with
primary oral medical treatment for Mycobacterium ulcerans infection.
Methods
Ethics Statement
This is an observational cohort study, approved by Barwon
Health’s Human Research and Ethics Committee. All previously
gathered human medical data were analysed anonymously.
Data on all confirmed M. ulcerans cases managed at Barwon
Health has been collected prospectively since January 1998. From
October 2010, our standard treatment practice for initial M.
ulcerans lesions has comprised combination antimicrobial therapy,
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with limited surgical debridement performed to aid wound
healing. The data extracted from medical records included;
patient demographics and co-morbid conditions, details of the MU
lesion, regimen and duration of antimicrobial therapy, and details
of surgical procedures. Cases treated between October 2010 and
December 2011 with 12 months follow-up were included in this
cohort.
Definitions
A M. ulcerans case was defined as the presence of a lesion
clinically suggestive of M. ulcerans plus any of (1) a culture of M.
ulcerans from the lesion, (2) a positive Polymerase Chain Reaction
(PCR) from a swab or biopsy of the lesion, or (3) histopathology of
an excised lesion showing a necrotic granulomatous ulcer with the
presence of acid-fast bacilli (AFB) consistent with acute M. ulcerans
infection.
The anatomical location of a M. ulcerans lesion was described as
distal if it was on the elbow or below, or on the knee or below
[7,10].
Primary medical treatment was defined as treatment of a M.
ulcerans lesion with either antimicrobials alone or antimicrobials in
conjunction with limited surgical debridement. Drug dosages for
adults included ciprofloxacin 500 mg twice daily, moxifloxacin
400 mg daily, rifampicin 10 mg/kg/day (up to a maximum of
600 mg daily), and clarithromycin 500 mg twice daily.
Paradoxical reactions were defined by the presence of one or
both of the following features: a) clinical: an initial improvement
on antibiotic treatment in the clinical appearance of a M. ulcerans
lesion followed by deterioration of the lesion or its surrounding
tissues, or the appearance of a new lesion(s), and b) histopathology:
examination of excised tissue from the clinical lesion showing
evidence of an intense inflammatory reaction consistent with a
paradoxical reaction [11].
Limited surgical debridement was defined as curettage of the
lesion or a minor excision to remove excess granulation tissue and
to debride ulcer margins, with or without the use of a split skin
graft (SSG). Limited surgical debridement was undertaken
primarily to remove necrotic tissue from the MU lesion in order
to promote healing by secondary intention.
Patients who underwent extensive surgery (defined as complete
excision of the entire lesion including margins of non-necrotic
tissue, with either direct closure or the use of a SSG or a
vascularised skin and tissue flap for reconstruction or to cover the
defect) were excluded from the formal analysis.
Criteria for primary medical therapy in our practice includes;
patient willingness to take antimicrobials, and no contraindications
to antimicrobial therapy (for example; drug interactions, or severe
liver disease).
Criteria for complete surgical excision include factors such as; a
lesion suitable for removal with direct wound closure, need for
reconstruction to close a skin defect via flap or SSG, patient unable
or unwilling to take antimicrobials, and patient or surgeon
preference.
Definitions of treatment success, treatment failure, disease
recurrence, and immune suppression were as published previously
[2,5].
A complication of medical therapy was defined as an adverse
event attributed to an antibiotic that required cessation of that
medication.
Data was collected using Epi-Info 6 (CDC, Atlanta) and
analysed using STATA 12 (StataCorp, Texas, USA). Categorical
values were compared using the Mantel-Haenszel test and median
values were compared using the Mann-Whitney test.
Results
From 1/10/2010 through 31/12/11, there were 54 patients
with MU infection managed at Barwon Health. From this cohort
11 patients (20%) were excluded from further analysis; 3 patients
underwent primary complete surgical excision alone, and 8
patients were prescribed antimicrobials but also underwent
complete surgical excision. There were no significant differences
in baseline characteristics of those excluded from those included in
the analysis (table 1).
Forty-three (80%) patients were therefore included in this
analysis. Baseline characteristics can be seen in table 1. All patients
were primarily managed as outpatients. The majority of patients
were male (65%), and the median age was 50.2 years (range 1.5–
87.9 years). Lesions were ulcerative in 91% and WHO stage 1 in
86% of patients. All patients resided in areas of the Bellarine
peninsula where MU is endemic; the majority residing in Point
Lonsdale (36%) and Barwon Heads (29%). Four patients (9%) had
known co-morbidities including diabetes (2), immune suppression
(1), and malignancy (1). No patients were known to be HIV-
infected though active screening was not performed.
Antimicrobial regimens were all rifampicin-based. Rifampicin
was combined with; ciprofloxacin in 30 (70%) patients, clarithro-
mycin in 12 (28%) patients, and moxifloxacin in 1 (2%) patient.
The median duration of therapy was 56 days (range 28 to 91 days).
Seven of 43 patients (16%) received less than 56 days of therapy.
Antibiotic-associated complications requiring cessation of one or
more antibiotics occurred in 7 of 43 patients (16%). Two patients
developed complications attributed to the combination of rifam-
picin and ciprofloxacin, 2 patients developed complications
attributed to ciprofloxacin, 1 patient developed complications
due to moxifloxacin, and 2 patients developed complications due
to rifampicin. The most common complications were gastrointes-
tinal upset in 4 patients, joint aches in 2 patients, hepatitis in 2
patients, tendonitis in 1 patient and thrombocytopenia in 1
patient. Of the 11 patients who underwent complete excision and
were excluded from the study cohort, 2 of those 8 who took
antibiotics developed complications.
Nine of 43 patients (21%) developed paradoxical reactions a
median of 34 days after antibiotic therapy initiation (IQR 20–92
days).
Five of 43 (12%) medically managed patients also underwent
limited surgical debridement, and 3 of these procedures involved a
SSG for coverage of the defect.
Overall, 42 of 43 patients (98%) were cured with primary
medical therapy. Cosmetic outcomes were excellent in these
Author Summary
Mycobacterium ulcerans (MU) is responsible for disfiguring
skin infections which are challenging to treat. The
recommended treatment for MU has continued to evolve
from surgery to remove all involved tissue, to the use of
effective combination oral antibiotics with surgery as
required. Our study describes the oral medical treatment
utilised for consecutive cases of MU infection over a 15
month period at our institution, in Victoria, Australia.
Managing patients primarily with oral antibiotics results in
high cure rates and excellent cosmetic outcomes. The
success with medical treatment reported in this study will
aid those treating cases of MU infection, and will add to
the growing body of knowledge about the relative roles of
antibiotics and surgery for treating this infection.
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medically managed MU cases (Figures 1 & 2). One patient failed
primary medical therapy. This patient was a 17 month-old boy
who presented with a nodular MU lesion on his arm of 1 cm
diameter. He completed 56 days of rifampicin (10 mg/kg/day)
with clarithromycin (13 mg/kg/day in twice daily dosing) both in
liquid formulations with initial reduction in the size of the lesion.
Four months after antimicrobials were completed the lesion
enlarged and was debrided. Tissue from the debridement was
culture positive for M. ulcerans. The patient was re-treated with
rifampicin (10 mg/kg/day) and clarithromycin (13 mg/kg/day in
twice daily dosing) both in liquid formulations, with subsequent
ulceration of the nodule. A paradoxical reaction was diagnosed 4
weeks after re-treatment commenced based on the clinical
deterioration of the lesion and was treated with prednisolone at
a dose of 1 mg/kg for 4 weeks. The ulceration progressed and
ultimately extended over an area of 1265 cm and healed fully by
secondary intention over a period of 9 months (16 months after
initial treatment).
Discussion
Combination antimicrobial therapy is now routinely recom-
mended to treat Mycobacterium ulcerans infection with or without the
addition of surgical intervention [4–6,12]. Here we describe our
experience with primary medical management of MU infection in
South-eastern Australia using oral rifampicin-based regimens and
we demonstrate the efficacy and safety of this approach with
healing of lesions within 12 months of therapy initiation in 98% of
cases, an acceptable toxicity profile and good cosmetic results.
In our study, the median duration of therapy was 8 weeks,
although over 15% of patients completed less than 56 days of
therapy. Previous data from Etuaful and others demonstrated
viable MU organisms in tissue after 2 weeks of therapy, but not
after 4, 8 or 12 weeks of therapy [13]. We reported that
mycobacterial cultures were positive in excised specimens from the
majority of patients (55%) who received less than 14 days of
antibiotic therapy, but in only 1 of 8 patients (12.5%) who received
more than 14 days of treatment [5]. Although WHO recommends
combined antibiotic treatment for 8 weeks as first-line therapy for
all M. ulcerans lesions [12], shorter durations of antimicrobials may
be adequate in selected patients and further research should be
performed to explore this possibility [7].
In the recent MU antimicrobial therapy literature, some
differences exist in the inclusion or exclusion of patients who
underwent surgery. In addition, there are likely geographic
differences in surgical practice. In Chauty’s medically treated
cohort, 37% of patients underwent limited surgery, (and 13%
underwent extensive surgery), while in Sarfo’s study, 5% of
patients underwent SSG while the remaining 95% healed without
surgery [4,7]. In the present study, 12% of medically managed
patients underwent limited surgery (including minimal debride-
ment and SSG) to promote wound healing and closure, and we
excluded patients who underwent extensive surgery.
The selection of patients for medical therapy has not been
clearly defined, and size of the MU lesion may or may not be a
useful criterion. While smaller (WHO category 1) lesions are likely
to achieve cure with medical therapy, they are also likely to be
suitable for surgical excision with direct closure. WHO category 1
lesions have been shown to heal with medical therapy after a
median of 12–18 weeks [4,6]. In contrast, large lesions (WHO
categories 2 and 3) may require more disfiguring surgery to
achieve healing, while medical therapy for these lesions may result
in slow but gradual shrinkage and secondary healing. The healing
of larger lesions (WHO categories 2 and 3) is variable, and occurs
anywhere from 11–15.5 weeks [4], to 30 weeks after initiation of
antimicrobials [6]. In our cohort, the majority of patients (81%)
who underwent surgical excision had WHO category 1 lesions. In
some other studies of medical therapy for MU, researchers have
only included lesions less than 10 cm in cross-sectional diameter
[6,7], while we and others have included lesions of all sizes [4].
Antimicrobial therapy for MU appears to be safe and
reasonably well tolerated. In a study of rifampicin and
streptomycin therapy, treatment was well tolerated with only 3
of 160 patients (1.8%) developing side effects [4]. In a pilot study
of oral chemotherapy for MU infection, the authors described
rifampicin and clarithromycin in combination as well-tolerated
with no adverse effects [7]. It is worthy to note that in their
Table 1. Baseline characteristics of patient cohort.
Characteristics
Medical Management (43
patients)
Surgical Management (11
patients) p-value
Median Age (IQR) 50.2 years (26.7–75.1 years) 53.3 years (40.2–64.5 years) 0.76
Male gender 28 (65.1%) 5 (45.5%) 0.23
Median duration symptoms prior to diagnosis (IQR) 35 days (21–75 days) 60 days (30–90 days) 0.24
Lesion type
Ulcer 39 (90.7%) 11 (100%) 0.57
Nodule 3 (7.0%) 0 (0%) 0.57
Oedematous 1 (2.3%) 0 (0%) 0.57
WHO stage
1 37 (86.1%) 9 (81.2%) 0.56
2 4 (9.3%) 2 (18.8%) 0.56
3 2 (4.7%) 0 0.56
Lesion location
Lower limb 29 (65%) 4 (36.4%) 0.06
Upper limb 14 (35%) 7 (63.6%) 0.06
doi:10.1371/journal.pntd.0002315.t001
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cohort of 30 patients, all were hospitalized during therapy, which
would be expected to both boost adherence and manage minor
side effects more easily [7]. In our cohort, 7 of 43 patients (16%)
ceased one or more antibiotics due to side effects. This rate of
side effects is in keeping with rates our group previously described
for rifampicin, clarithromycin and ciprofloxacin, which were
higher than rates reported in younger populations in Africa [4].
We believe the older median age of our cohort may explain
reduced drug tolerability, but that overall the side effect profile is
acceptable [5].
Antimicrobial therapy has been demonstrated to improve MU
lesion healing and prevent relapse. In non-controlled trials,
rifampicin-based regimens in conjunction with clarithromycin
[7], or a fluoroquinolone [5,11], have demonstrated success in
managing MU infection. Our antimicrobial treatment success rate
of 98% is in keeping with other studies of medical management of
MU [4,6,7]. In Sarfo’s study of 160 patients, and Chauty’s cohort
of 30 medically managed patients there were no recurrences or
relapses during 1 year of follow-up after treatment initiation [6,7].
In Nienhuis’s study, there was a 1.4% recurrence rate [4], and in
our cohort of 43 patients we describe one relapse in a patient with
a nodular form of MU infection.
Although the cure rates described in our Australian cohort are
comparable to studies conducted in Africa [4,6,7], it is possible
these outcomes could be influenced by identified small differences
in M. ulcerans genomic sequences. M. ulcerans strains worldwide
produce a very restricted repertoire of mycolactones, although
Australian strains characteristically produce predominantly myco-
lactone C compared with predominantly mycolactone AB
produced in Africa [14]. In addition, M. ulcerans has evolved by
acquiring a plasmid (pMUM) and other independent genomic
changes within strains from different areas to produce region-
specific phenotypes and genotypes [15,16]. However, recent
analysis has revealed that Buruli ulcer in Africa and Australia is
caused by one distinct lineage of mycolactone-producing Myco-
bacteria comprising a highly clonal group [17]. This close genetic
relationship suggests that strain differences are minimal and there
is currently no evidence to suggest that these strain differences
significantly influence responses to therapy or cure rates. There
are however some differences between patient populations in our
study and those conducted in Africa. For example, the median age
in our cohort was 50 years compared with 12 years in studies
conducted in Ghana [4,6]. In our study over 90% of lesions were
ulcerated, compared with 36–70% in African cohorts [4,6,7], and
none of our patients were HIV infected compared with 2% in
Ghana [6]. Finally, there are possible unmeasured differences in
nutrition and innate response to infection that may affect cure
rates in different geographic regions.
Figure 1. Mycobacterium ulcerans lesion at commencement of antimicrobial therapy.
doi:10.1371/journal.pntd.0002315.g001
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There are a number of potential reasons for the relapsed case
seen in our study. Firstly, it may relate to the nodular form of
disease as medical management is thought to be sufficient for
ulcerative lesions but some believe that most non-ulcerative lesions
require additional surgery [7]. It may be more difficult to sterilize
lesions that don’t ulcerate and discharge the underlying necrotic
material containing large numbers of mycobacteria. Secondly, it is
possible that the ulceration of this nodule was part of the natural
history of nodular MU disease, as has been described by Nienhuis
and others [18], whereby most nodules ulcerate during the healing
process. However the fact that the area of ulceration was
significantly larger than the initial nodule and the lesion remained
culture positive 6 months after antibiotics commenced argue
against this. Finally, it is possible that the liquid preparations of
antimicrobials used in this case contributed to treatment failure. It
has been shown that the bioavailability of rifampicin varies
depending on the drug preparation [19]. Furthermore, experience
suggests that the use of syrups in young children can adversely
affect adherence potentially leading to under dosing. Thirdly, it
may be that recommended doses of antimicrobials in young
children are inadequate, especially as no specific research has been
performed on drug levels in this age-group for MU treatment.
Research in children hospitalized for treatment of tuberculosis has
found that their serum rifampicin concentrations were consider-
ably less than the suggested lower limit for 2-hour rifampicin
concentrations in adults after receiving standard rifampicin
dosages similar to those used in adults [20]. This study however
utilized fixed-dose combination tablets formulated for paediatric
use, which is not comparable to the preparation used in our
patient.
There are limitations to our study; firstly it’s observational
design and the exclusion of 20% of patients during the study
period as they underwent excisional surgery. Although there were
no significant differences in baseline characteristics between this
group and those included, it is possible that there were other
unknown confounders that may have introduced a selection bias
and affected the validity of our findings [4,6,7]. Secondly, we are
unable to detail the exact timing of healing of MU lesions, which
would be valuable information. Finally, most of the lesions treated
in our study (86%) were WHO Category 1 lesions and therefore
the strength of our evidence for treatment success for lesions of
larger size is weaker, although there have been descriptions in the
literature of good success rates with medical therapy for lesions
larger than 5 cm [6,7].
Conclusions
Our experience demonstrates the efficacy and safety of primary
oral medical management of M. ulcerans in an Australian cohort.
Further research is required to determine the optimal andminimum
durations of antimicrobial therapy and the most effective dosages
and formulations of antimicrobials for young children.
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Figure 2. Mycobacterium ulcerans lesion 9 months after antimicrobial therapy commenced.
doi:10.1371/journal.pntd.0002315.g002
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